SCM
DMII

Shaolin Capital Management’s Drugs Made In America Acquisition II Corp DMII Stock Holding History

Shaolin Capital Management’s Portfolio DMII Stock Details DMII Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.82M Sell
180,484
-244,516
-58% -$2.45M 0.09% 222
2026
Q1 		$4.24M Hold
425,000
– – 0.16% 95
2025
Q4 		$4.21M Buy
+425,000
New +$4.2M 0.13% 95

Other funds holding DMII

KIM
Karpus Investment Management Pittsford, New York $3.48B AUM 10.49% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
TCM
Tenor Capital Management New York $7.09B AUM 3.55% 1-Year Est. Return

Shaolin Capital Management's DMII Position: Q2 2026 in Review

Shaolin Capital Management reduced its Drugs Made In America Acquisition II Corp (DMII) stake by 58% in Q2 2026, selling an estimated $2.45M and leaving 180,484 shares worth $1.82M. The position accounts for 0.09% of the portfolio, ranked #222.

Shaolin Capital Management first reported a position in DMII in Q4 2025 and has held it in 3 quarters since. The position peaked at $4.24M in Q1 2026. 69 funds tracked by Wall St. Rank hold DMII as of Q2 2026.

  • Shaolin Capital Management held 180,484 shares of Drugs Made In America Acquisition II Corp worth $1.82M as of Q2 2026.
  • Shaolin Capital Management sold 244,516 Drugs Made In America Acquisition II Corp shares in Q2 2026, an estimated $2.45M.
  • Drugs Made In America Acquisition II Corp made up 0.09% of Shaolin Capital Management's portfolio in Q2 2026, its #222 holding.
  • Shaolin Capital Management first reported a position in Drugs Made In America Acquisition II Corp in Q4 2025 and has held it in 3 quarters since.
  • Shaolin Capital Management's Drugs Made In America Acquisition II Corp position peaked at $4.24M in Q1 2026.
  • 69 funds tracked by Wall St. Rank held Drugs Made In America Acquisition II Corp as of Q2 2026.

Based on Shaolin Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.